We are underestimating the downside of our current system when we contemplate change. We need to take some risks to do better. #abimf2013

A clinic visit is never routine for our patients. It can be the event of their week or even their month. Writing about the day I finally understood that. Read the new Editor’s Page in JACC: “The Day I Became a Doctor” https://t.co/3xS3odL7Te @JACCJournals @YaleMed

After two years and thousands of manuscripts, I’ve learned that the real work of an editor isn’t gatekeeping — it’s partnership. My latest @JACCJournals Editor’s Page: The Partnership 🔗 https://t.co/pii9UDzvKs #MedTwitter #AcademicMedicine #Cardiology @YaleMed @YaleSPH

TCA PODCAST: WATCH this clip with children's book expert Megan Cox Gurdon, WJS columnist and author of the Enchanted Hour on the importance of reading aloud: "When someone is reading aloud and there's a group of people listening to a story and it might be a classroom or a

@JACCJournals And be sure to check out our Adipokine Explorer! https://t.co/VPlaKeAR8G

@JACCJournals Here is my substack on the topic: Fat, Reframed. https://t.co/WGRIWstG8x

@JACCJournals - we are about ideas and science. We are working to advance cardiovascular health; and to be the place to spark dialogue about new ideas.

HFpEF is one of medicine’s biggest puzzles. Maybe the answers lie not in the heart alone, but in the cross-talk between fat and myocardium. Read the full JACC Adipokine Spotlight and join the conversation. 🔗 https://t.co/uy3fbcwzk6 #JACC #HFpEF #Cardiology #AdipokineHypothesis

The issue invites disagreement and testing. Some cases of HFpEF may not fit the model. But frameworks like this push the field forward—helping us ask sharper questions and design better studies.

Themes emerge: • It’s about fat distribution, not just BMI. • Adipokines act through endocrine-paracrine signaling. • Sex, race, and metabolic context all shape expression and risk. • New therapies (GLP-1RA, SGLT2i) may restore adipokine balance.

To deepen the discussion, we invited experts across cardiology and metabolism to weigh in: Erica Spatz: A Turning Point Carolyn Lam/Dalane Kitzman: From Pariah to Paradigm Subodh Verma/Deepak Bhatt: Parsing the Adipokine Axis Faiez Zannad, Jennifer Ho, Robert Mentz, and others.

As Editor-in-Chief, I wrote about why JACC published it: Because progress in medicine requires ideas that connect disciplines and challenge assumptions. 🧠 “Ideas Worth Testing: The Adipokine Hypothesis.” https://t.co/mGP8yvempA

In this 25,000-word State-of-the-Art Review, Packer unites >1,800 references to build a testable framework explaining how dysfunctional adipose tissue could underlie HFpEF. It’s bold, ambitious—and worth debating.

Dr. Milton Packer proposes that hypertrophied, inflamed fat cells secrete molecules—adipokines—that drive cardiac remodeling, inflammation, and fibrosis. In other words: HFpEF may begin in fat, not the heart.

After decades of disappointment in HFpEF, a new idea is shaking things up. Could heart failure with preserved EF actually be an adipose-driven disease? JACC’s latest issue explores “The Adipokine Hypothesis.” @JACCJournals 🔗 https://t.co/uy3fbcwzk6

always great to be in the studio with @thehowie

What everyone needs to read: @JACCJournals: Global Burden of CVD 🚨CVD remains the leading cause of disease burden & death worldwide with geographic variations 🫀CVD burden: explained substantially by known, modifiable risk factors that are inadequately controlled- particularly

ER failures, AI in hospitals, new hypertension drugs, vaccine politics, and two Nobel Prizes — one right here at Yale. This week’s Health & Veritas podcast covers it all. Read more: https://t.co/CFirk5DRdW @YaleSPH @YaleSOM @YaleMed

Off to #Warsaw for Prevention & Intervention meeting. Will get reading catch up time on the flight. ⁦@JACCJournals⁩ ⁦@aayshacader⁩ ⁦@SABOURETCardio⁩

Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals 80% (!) of CV disease burden is attributable to modifiable RFs Top modifiable risks in 2023: ⚠️ High systolic BP ⚠️ Dietary risks ⚠️ High LDL cholesterol ⚠️ Air pollution 🔗 https://t.co/EIvzZMQQPC

Fibrinolytic therapy remains a major mgmt option for thromboembolic diseases. Advances in catheter-directed techniques, dosing strategies, & novel agents may expand therapeutic options & improve the safety of fibrinolytic therapy. https://t.co/pTAdP6G1oc #JACC @bbikdeli @hmkyale

We authored this state-of-the-art review, now published in JACC, to provide an updated, comprehensive overview of post–myocardial infarction inflammatory mechanisms and to critically evaluate the emerging clinical evidence on anti-inflammatory therapies for secondary